Candel Therapeutics, Inc. (CADL) Stock Price & How to Invest
Last updated November 2026
Short answer
Candel Therapeutics (CADL) is a clinical-stage biotech with no product revenue, so the stock is a bet on one approval: aglatimagene besadenovec (CAN-2409) for localized prostate cancer, which met its Phase 3 primary endpoint. On November 12, 2026 Candel pushed the planned FDA filing from late 2026 to mid-2027, and the shares fell about 37% to roughly $5.25 before the open on November 13. They closed at about $5.11 on November 20, 2026, a market value near ~$401M, down ~6.1% year to date.
CADL stock price
As of 2026-11-20, Candel Therapeutics, Inc. (CADL) last closed at $5.04, up 10.8% over the past year. Over the past 52 weeks it has traded between $4.42 and $13.75.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Candel Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
CADL key stats
At $5.04 on November 20, 2026, Candel Therapeutics, Inc. (CADL) has a market cap of $395M.
- Market cap
- $395M
- Price to book
- 3.0
Market cap, P/E and yield are measured at the $5.04 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Candel Therapeutics, Inc. (CADL)?
The last two weeks for Candel Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- CADL closed at $5.04 on November 20, 2026, down 18.7% over the past five trading days (from $6.20).
- On November 16, 2026, Citigroup lowered its target to $20.00 from $26.00 (Buy).
- On November 13, 2026, HC Wainwright & Co. lowered its target to $18.00 from $23.00 (Buy).
- On November 13, 2026, Canaccord Genuity lowered its target to $13.00 from $25.00 (Buy).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Candel Therapeutics, Inc. (CADL) do?
Candel Therapeutics is a Needham, Massachusetts biotech that builds viral immunotherapies: modified viruses injected straight into a tumor to make the immune system see it. Its lead drug, aglatimagene besadenovec (CAN-2409), is an adenovirus carrying a gene that, paired with the oral antiviral valacyclovir, kills tumor cells and releases tumor antigens. A second platform uses a modified herpes virus, linoserpaturev (CAN-3110), now in a Phase 1b trial in recurrent high-grade glioma. Candel sells nothing yet, so every dollar of spending comes from equity and debt.
The third quarter of 2026, reported November 12, showed a net loss of ~$21.9M, up from ~$11.3M a year earlier. Research spending rose to ~$15.6M from ~$8.5M on trial and manufacturing costs, and administrative costs rose to ~$7.4M from ~$4.7M as the company prepared for a commercial launch. Cash was ~$203.1M on September 30, helped by a ~$100M share sale at $5.45 in February 2026 and the first ~$50M of a $130M Trinity Capital loan. Management says that cash lasts into the second quarter of 2028. The same release moved the Biologics License Application (BLA) for prostate cancer from the fourth quarter of 2026 to mid-2027, citing timelines for certain assay refinements and ongoing talks with the FDA.
That delay is why the stock is trending. Shares closed at ~$8.39 on November 12, traded near ~$5.25 before the open on November 13, and closed at ~$5.11 on November 20, 2026, a market value of roughly ~$401M on ~78M shares. With ~$203M of cash and ~$50M of debt, the market is assigning about $250M of value to the whole pipeline, including a drug with positive Phase 3 data under a Special Protocol Assessment. Stifel kept a Buy rating but cut its target to $19 from $22, saying commercial launch now looks like mid-2028, and BofA Securities cut its target to $15 from $18. The investment case rests on the prostate filing going in on the new date, an FDA approval, and the Phase 3 AURORA lung cancer trial, which started enrolling this quarter.
What's driving Candel Therapeutics, Inc. (CADL)?
1. The prostate cancer filing in mid-2027
The PrTK03 Phase 3 trial tested aglatimagene plus valacyclovir added to standard radiation in intermediate-risk localized prostate cancer, against placebo plus radiation. At a median follow-up of 58 months, patients on the drug had a 41% lower risk of recurrence or prostate cancer-specific death (p=0.0034). At two years, 80% of treated patients had negative biopsies versus 63% of controls. The trial ran under a Special Protocol Assessment, an FDA agreement on design and endpoints, and the drug has Fast Track and RMAT designations, which allow rolling review and closer FDA contact. A filing in mid-2027 and a standard review would put a decision around mid-2028, the date Stifel now uses for launch.
2. Manufacturing readiness
Candel says it has finished a process validation campaign for drug substance and drug product at its contract manufacturer, has made clinical material with the new process, and is testing validation batches meant for commercial supply. For a viral gene therapy, chemistry, manufacturing and controls (CMC) work is often what decides whether a BLA is accepted and approved on time. The delay announced in November was tied to assay refinement, which sits in this same body of work. Investors will look for the company to confirm, probably in early 2027, that the assays are locked and that the FDA agrees on the package. Any further slip would likely push the launch into late 2028 and shorten the gap before cash runs out.
3. AURORA, the Phase 3 lung cancer trial
Candel's second large opportunity is metastatic non-squamous non-small cell lung cancer (NSCLC) in patients whose disease kept growing on checkpoint inhibitors such as Keytruda. In a Phase 2a trial published in the Journal for ImmunoTherapy of Cancer, patients given aglatimagene with continued checkpoint therapy had a median overall survival of ~24.5 months in the evaluable group. Standard chemotherapy (docetaxel) in this setting has historically produced survival closer to a year. AURORA randomizes patients 1:1 to aglatimagene plus continued pembrolizumab or to docetaxel, with overall survival as the primary endpoint, across ~150 planned sites. The first site opened in the third quarter of 2026, so results are several years away, but the trial gives the stock a second shot beyond prostate cancer.
4. Funding through approval
Candel had ~$203M of cash on September 30, 2026 and reported operating expenses of ~$23M in the third quarter, up from ~$13M a year earlier as AURORA and launch preparation ramp. Management guides that cash reaches into the second quarter of 2028, which is close to the new expected approval window. The Trinity Capital facility has up to ~$80M more available: two tranches totaling $50M tied to milestones and a $30M tranche at the lender's discretion. If milestones shift with the BLA, access to that money could shift too. The cheaper path would be raising equity after an approval, while a raise near today's lower price would dilute holders more than the February sale at $5.45 did.
What are the risks to Candel Therapeutics, Inc. (CADL)?
The main risk is regulatory. The BLA has already moved once, from late 2026 to mid-2027, and the company says the timing still depends on FDA discussions, so another delay is possible. The FDA could also question the trial's endpoint, the size of the benefit, or the comparison with current care, which in intermediate-risk patients often adds short-course hormone therapy to radiation. Manufacturing is a second risk: viral gene therapies have drawn FDA complete response letters over CMC issues, and assay work is the cause of the current delay. Financing is a third. Cash lasts into Q2 2028, about when an approval could come, so a further slip probably means raising money at a depressed share price; the Trinity loan's later tranches depend on milestones. Lung cancer is a fourth: AURORA is a large, costly trial and a Phase 2a survival figure from a single-arm study often shrinks in randomized testing. Short interest was ~17% of shares outstanding before the drop, which can make the stock move sharply in both directions. With no revenue, the share price has no earnings floor.
What is the Candel Therapeutics, Inc. (CADL) forecast?
9 analysts publish price targets on CADL, averaging $17.67 as of November 2026, or +250.6% against the $5.04 share price on November 20, 2026. The published targets run from $11.00 to $29.00, a wide spread, and the ratings split 10 buy, 0 hold, 0 sell. Over the last six months there have been 2 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full CADL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is CADL a buy or a sell?
We give no verdict on Candel Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. The prostate cancer filing in mid-2027. The PrTK03 Phase 3 trial tested aglatimagene plus valacyclovir added to standard radiation in intermediate-risk localized prostate cancer, against placebo plus radiation. The most optimistic published target, $29.00, assumes this works close to its best case.
The case against. The main risk is regulatory. The most pessimistic target, $11.00, is roughly what CADL is worth if this bites instead.
Read the full bull and bear case on CADL, including what would have to change to break either one. Walnut is not an investment adviser.
How is Candel Therapeutics, Inc. (CADL) valued?
Market cap, P/E and dividend yield at today's price are in the CADL key stats above. The business figures below come from Candel Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$0; no approved products
- Net loss: ~$21.9M in Q3 2026 (EPS about -$0.28 vs ~-$0.31 expected); ~$69.6M for the first nine months
- Operating expenses: ~$23.0M in Q3 2026, up from ~$13.2M a year earlier
- Cash (Sept 30, 2026): ~$203M; runway guided into Q2 2028
- Debt: ~$50M drawn on a $130M Trinity Capital term loan
- Analyst view: Average target ~$17.67 across 9 analysts (November 2026), down from ~$22 before the delay
As of November 2026: With no sales, Candel is valued on its pipeline. At about $5.11 per share on November 20, 2026, the market cap is about $401M and enterprise value about $250M after netting ~$203M of cash against ~$50M of debt. That is the price the market puts on a drug with positive Phase 3 prostate data, a Phase 3 lung trial just started and an early glioma program. Analysts' average target was ~$22 before the delay and is about ~$17.67 across nine analysts after cuts from Stifel (to $19) and BofA (to $15), which shows how much of the gap depends on approval timing and dilution. A clean filing in mid-2027 or a further slip would likely move this valuation more than any quarterly loss figure.
Who competes with Candel Therapeutics, Inc. (CADL)?
Standard care in localized prostate cancer
Aglatimagene would be added to radiation, so its real competition is current practice: external beam radiation, often with short-course hormone therapy such as leuprolide or Sumitomo Pharma's oral relugolix (Orgovyx), and surgery. Doctors will weigh an extra injected therapy against that familiar routine, which shapes how fast any approved product is adopted.
Viral and gene-based cancer therapies
Amgen's Imlygic (an oncolytic herpes virus for melanoma), Ferring's Adstiladrin (an adenovirus gene therapy for bladder cancer), CG Oncology's cretostimogene and Replimune's RP1 work on related ideas. Their regulatory paths, including FDA objections over trial design and manufacturing, are the closest guide to how reviewers may treat Candel's filing.
Second-line lung cancer treatments
In NSCLC after checkpoint inhibitors, AURORA compares directly with docetaxel chemotherapy. Antibody-drug conjugates such as AstraZeneca and Daiichi Sankyo's Datroway, plus bispecific antibodies and cell therapies in late trials, are all chasing the same patients, so the bar for a survival benefit is likely to keep rising while AURORA runs.
What stocks are similar to Candel Therapeutics, Inc. (CADL)?
Other names that sit close to CADL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Candel Therapeutics, Inc. (CADL)
There are three common ways to get CADL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CADL sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where CADL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Candel Therapeutics, Inc. (CADL)
CADL has positive Phase 3 prostate data, ~$203M in cash and a runway into Q2 2028, but the filing is now mid-2027, so approval and revenue sit roughly a year further out.
More on Candel Therapeutics, Inc. (CADL)
Whether CADL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CADL a buy or a sell?, and where the stock could go from here in the CADL stock forecast.
For income investors, whether CADL pays a dividend and how the payout looks is covered in does CADL pay a dividend? And to weigh CADL against a peer, read the full side-by-side comparisons: CADL vs AMGN and CADL vs CG.
Wondering how CADL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Candel Therapeutics, Inc.
Ask Walnut's AI anything about CADL and see how it fits what you own.
FAQ
Why did CADL stock fall on November 13, 2026?
+
On November 12, alongside its third-quarter results, Candel said it now expects to submit the BLA for aglatimagene besadenovec in localized prostate cancer in mid-2027. The prior target was the fourth quarter of 2026, so the filing slipped about six months. The company cited timelines for certain assay refinements and said final timing depends on ongoing FDA discussions. Shares closed at ~$8.39 on November 12, already down ~9% on the day, and then traded near ~$5.25 before the open on November 13, a drop of roughly 37%. The stock had more than doubled earlier in 2026 on expectations of a year-end filing, which made the reaction to the delay larger. Stifel cut its price target to $19 from $22 and kept a Buy rating, saying launch expectations move to mid-2028.
What is aglatimagene besadenovec (CAN-2409)?
+
Aglatimagene besadenovec is an adenovirus engineered to carry the herpes simplex virus thymidine kinase gene. It is injected directly into the tumor, and the patient then takes valacyclovir, a common oral antiviral. Inside infected tumor cells, the enzyme turns valacyclovir into a toxic compound that kills those cells. As the cells die, they release tumor antigens, and the virus itself draws immune cells in, so the treatment works partly as a local vaccine against the patient's own cancer. Candel reported that in its PrTK05 Phase 2 study, treated patients showed higher levels of CD8+ T cells and memory T cells in the blood. The drug holds Fast Track and RMAT designations in prostate cancer, Fast Track in NSCLC, and Fast Track plus Orphan Drug designations in pancreatic cancer.
How strong were the Phase 3 prostate cancer results?
+
In the PrTK03 Phase 3 trial in intermediate-risk localized prostate cancer, adding aglatimagene and valacyclovir to radiation cut the risk of recurrence or prostate cancer-specific death by 41% versus placebo plus radiation (p=0.0034), at a median follow-up of 58 months. In the exploratory longer follow-up, Candel reported improvements of 52% in time to biochemical failure, 49% in time to salvage therapy and 90% in time to metastasis. At two years, 80% of treated patients (n=167) had negative biopsies, against 63% of controls (n=62). The trial ran under a Special Protocol Assessment, which records FDA agreement on the design. These are company-reported figures, and the FDA will reach its own view of the data and the benefit for patients during review.
Does Candel Therapeutics make money?
+
No. Candel has no approved products and no product revenue. It reported a net loss of ~$21.9M in the third quarter of 2026 and ~$69.6M for the first nine months, and its accumulated deficit reached ~$300M. The nine-month loss is far larger than the ~$8.7M loss for the same period of 2025, partly because 2025 included a ~$21.7M non-cash gain on warrant liabilities and partly because spending roughly doubled. Operating expenses were ~$66M for the nine months as the company ran trials, validated manufacturing and built commercial readiness. Revenue would depend on FDA approval of aglatimagene in prostate cancer, which on the new timeline could come around mid-2028 if the filing is accepted and reviewed on a standard schedule.
How long will Candel's cash last?
+
Candel had ~$203.1M in cash and cash equivalents on September 30, 2026, up from ~$119.7M at the end of 2025. The increase came from a February 2026 offering of ~18.3M shares at $5.45, which raised ~$100M gross, and the first ~$50M tranche of a $130M term loan from Trinity Capital. Management says the cash funds its current plan into the second quarter of 2028. Two loan tranches totaling $50M depend on milestones and a final $30M tranche is at the lender's discretion. Because the expected approval window is also around mid-2028, the cushion between cash running out and possible launch revenue is thin, and a further raise before approval is a real possibility that investors watch.
What is CADL's valuation after the drop?
+
At the November 20, 2026 close of about $5.11, Candel's ~78M shares put its market value near ~$401M. Subtracting ~$203M of cash and adding ~$50M of debt gives an enterprise value of roughly ~$250M. A traditional price-to-earnings or price-to-sales ratio does not apply because the company has neither earnings nor sales. Biotech investors usually value a company like this by estimating peak sales for each drug, discounting for the chance of approval and the time to launch, and subtracting future dilution. Before the delay, the average analyst target was ~$22 across about 10 analysts, according to StockAnalysis. After the delay the average across nine analysts tracked by Yahoo Finance is about ~$17.67. Those targets assume approval, and they often move sharply after regulatory news, as Stifel's cut to $19 and BofA's cut to $15 showed.
Is there a lawsuit or merger involving Candel Therapeutics?
+
As of November 13, 2026, searches turned up no filed securities class action against Candel and no announced merger or acquisition agreement. After a sharp single-day drop tied to a regulatory timeline, law firms often announce investigations, and some of those later become filed complaints. An investigation notice is not a lawsuit, and a filed complaint would carry a case name and a court docket. Candel's 10-Q and 10-K reports on SEC EDGAR list any material legal proceedings. On the corporate side, the company remains independent, recently added Martine Zimmermann to its board and hired Maria Ostrovsky as general counsel effective November 3, 2026. A company with late-stage data and a low enterprise value can draw takeover interest, but nothing has been disclosed.
What else is in Candel's pipeline besides prostate cancer?
+
Aglatimagene is also in the Phase 3 AURORA trial in metastatic non-squamous NSCLC after checkpoint inhibitor failure, compared against docetaxel with overall survival as the primary endpoint. A published Phase 2a study showed a median overall survival of ~24.5 months in evaluable patients. Candel has completed Phase 2a trials in pancreatic cancer, where the drug has Orphan Drug status. Its second platform, linoserpaturev (CAN-3110), is a modified herpes virus in a Phase 1b trial in recurrent high-grade glioma, an aggressive brain cancer. Single-dose patients (n=50) had a median overall survival of 12.0 months, with 10% alive at three years. A repeat-dose group (n=12) showed 14.3 months median survival, with 5 of 12 alive at the July 2026 cutoff, though Candel calls those data immature.
How has CADL stock performed in 2026?
+
As of the November 20, 2026 close of about $5.11, Candel shares were down ~6.1% year to date but up ~15.6% over the past year. The swing inside the year was large: the stock reached ~$14.00 at its 52-week high on expectations of a late-2026 filing, then fell ~62% over three months and ~36% over the past month, most of it in the November 13 session after the BLA delay, which coverage called its worst ever. The 52-week low is ~$4.35. Past performance does not predict future returns.
How did Candel do in its latest quarter?
+
For the third quarter of 2026, reported November 12, Candel posted a net loss of ~$21.9M, about -$0.28 per share against a ~-$0.31 consensus, up from ~$11.3M a year earlier. Research spending rose to ~$15.6M and administrative costs to ~$7.4M as AURORA started and launch preparation ramped. Cash was ~$203.1M on September 30, with runway guided into the second quarter of 2028. The same release moved the prostate cancer BLA from the fourth quarter of 2026 to mid-2027, which drove the stock's reaction far more than the loss figure.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Candel Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.